FNAM (Evolutionary Genomics) 6-1 Month Momentum %: N/A% (As of Jul. 13, 2026)


FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics 6-1 Month Momentum %?

Evolutionary Genomics FNAM 31 6-1 Month Momentum % is N/A% as of Jul. 13, 2026. GuruFocus rates FNAM with a GF Score™ of 31/100.

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-07-13), Evolutionary Genomics's 6-1 Month Momentum % is N/A%.

The industry rank for Evolutionary Genomics's 6-1 Month Momentum % or its related term are showing as below:

FNAM's 6-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -18.12
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Evolutionary Genomics  (OTCPK:FNAM) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Evolutionary Genomics 6-1 Month Momentum % Related Terms

FNAM vs BXRX, GNCA, XSNX: 6-1 Month Momentum % Comparison

For the Biotechnology subindustry, Evolutionary Genomics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics 6-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's 6-1 Month Momentum % falls into.


FNAM
31GF Score
Evolutionary Genomics Inc FNAM
6-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics  (OTCPK:FNAM) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-1 Month Momentum % →
What does a 6-1 Month Momentum % of N/A% mean?
Evolutionary Genomics (FNAM) has a 6-1 Month Momentum % of N/A% as of Jul. 13, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' 6-1 Month Momentum % too high?
Evolutionary Genomics' current 6-1 Month Momentum % is N/A%. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' 6-1 Month Momentum % compare to BXRX and GNCA?
Evolutionary Genomics' 6-1 Month Momentum % of N/A% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current 6-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current 6-1 Month Momentum % of N/A%. The current 6-1 Month Momentum % is N/A%. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current 6-1 Month Momentum % is N/A% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price